Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Evaluation of a Novel Therapeutic Repetitive Transcranial Magnetic Stimulation Technique Optimized for Increased Accessibility in Major Depression
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
wasabi.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Evaluation of a Novel Therapeutic Repetitive Transcranial Magnetic Stimulation Technique Optimized for Increased Accessibility in Major Depression
Creator
Blumberger, Daniel
Daskalakis, Zafiris
Dees, Sinjin
Downar, Jonathan
Fox, Linsay
Hyde, Molly
Mansouri, Farrokh
Mir-Moghtadaei, Arsalan
Miron, Jean-Philippe
Sheen, Jack
Vila-Rodriguez, Fidel
Voetterl, Helena
Zhou, Ryan
Source
MedRxiv
abstract
ABSTRACT BACKGROUND Repetitive transcranial magnetic stimulation (rTMS) is effective in major depressive disorder (MDD). However, technical complexity and operational costs might have been barriers for its wide use and implementation in some jurisdictions, thereby decreasing accessibility. OBJECTIVE Our main goal was to test the feasibility of a novel rTMS protocol optimized for practicality, scalability and cost-effectiveness. We hypothesized that our novel rTMS protocol would be simple to implement and well-tolerated, but less costly and allow for more treatment capacity. METHODS Treatment was administered in an open-room setting, allowing a single technician to attend to multiple patients. Large non-focal parabolic coils held by custom-built arms allowed simple yet efficient and accurate placement. We employed a low-frequency (LF) 1 Hz stimulation protocol (360 pulses per session), delivered on the most affordable FDA-approved devices. MDD participants received an initial accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total), followed by a tapering course of daily sessions (up to 25) to decrease the odds of relapse. The self-reported Beck Depression Inventory II (BDI-II) was used to measure severity of depression. RESULTS Forty-eight (48) patients completed the arTMS course. No serious adverse events occurred, and all patients reported manageable pain levels. Response and remission rates were 35.4% and 27.1% on the BDI-II, respectively, at the end of the tapering course. CONCLUSION If rTMS could be delivered for lower cost at higher volume, while preserving efficacy, safety and tolerability, it could warrant further investigation of this treatment as a first-line intervention in MDD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04376697
has issue date
2020-06-17
(
xsd:dateTime
)
bibo:doi
10.1101/2020.06.15.20132092
has license
medrxiv
sha1sum (hex)
1d48fbdc54502dad9a03420f95f187b2e374dbda
schema:url
https://doi.org/10.1101/2020.06.15.20132092
resource representing a document's title
Evaluation of a Novel Therapeutic Repetitive Transcranial Magnetic Stimulation Technique Optimized for Increased Accessibility in Major Depression
resource representing a document's body
covid:1d48fbdc54502dad9a03420f95f187b2e374dbda#body_text
is
schema:about
of
named entity 'clinical practice'
named entity 'MDD'
named entity 'rTMS'
named entity 'June 17'
named entity 'medRxiv'
named entity 'rTMS'
named entity 'preprint'
named entity 'rTMS'
named entity 'neurostimulation'
named entity 'AEs'
named entity 'peer review'
named entity 'medRxiv'
named entity 'MDD'
named entity 'FDA'
named entity 'Parkinson's disease'
named entity 'Repetitive transcranial magnetic stimulation'
named entity 'physical distancing'
named entity 'peer review'
named entity 'preprint'
named entity '5.2'
named entity 'preprint'
named entity 'rTMS'
named entity 'rTMS'
named entity 'medRxiv'
named entity 'rTMS'
named entity 'depressive episode'
named entity 'relapse'
named entity 'antidepressants'
named entity 'preprint'
named entity 'rTMS'
named entity 'electromagnetic field strength'
named entity 'sensory impairment'
named entity 'medRxiv'
named entity 'rTMS'
named entity 'rTMS'
named entity 'positive feedback'
named entity 'medRxiv'
named entity 'preprint'
named entity 'preprint'
named entity 'clinically significant'
named entity 'depression'
named entity 'medRxiv'
named entity 'Suicide ideation'
named entity 'flexible scheduling'
named entity 'adverse events'
named entity 'preprint'
named entity 'rTMS'
named entity 'informed consent'
named entity 'antidepressant'
named entity 'psychotherapy'
named entity 'control arm'
named entity 'preprint'
named entity '4.2'
named entity 'MDD'
named entity 'preprint'
named entity 'range of motion'
named entity 'preprint'
named entity 'preprint'
named entity 'Canada'
named entity 'rTMS'
named entity 'medRxiv'
named entity 'Antidepressant'
named entity 'multiple sclerosis'
named entity 'traumatic brain injury'
named entity 'follow-up'
named entity 'MDD'
named entity 'controlled trial'
named entity 'substance dependence'
named entity 'cost-effectiveness'
named entity 'MDD'
named entity 'fatigue'
named entity 'empirical evidence'
named entity 'meta-analysis'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 3
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software